



Rec'd PCT/PTO 04 OCT 1996

Express Mail Number: EH 608540192 US

Rec'd PCT/PTO 04 OCT 1996

<p>FORM PTO-1390 (REV 5-93)</p> <p style="text-align: center;">U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p style="text-align: center;">TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</p>		<p>ATTORNEY'S DOCKET NUMBER</p> <p style="text-align: center;">96.1252.US</p> <p>US APPLICATION NO. (IF KNOWN, SEE 37 CFR § 1.5)</p> <p style="text-align: center;">08/722045</p>
<p>INTERNATIONAL APPLICATION NO.</p> <p>PCT/IE 95/00025</p>	<p>INTERNATIONAL FILING DATE</p> <p style="text-align: center;">April 6, 1995</p>	<p>PRIORITY DATE CLAIMED</p> <p style="text-align: center;">April 6, 1994</p>
<p>TITLE OF INVENTION</p> <p style="text-align: center;">EFFERVESCENT PHARMACEUTICAL FORMULATIONS CONTAINING CONTROLLED RELEASE BIODEGRADABLE MICROCAPSULES</p>		
<p>APPLICANT(S) FOR DO/EO/US</p> <p>Virginia Freeman Zebunnissa Ramtoola</p>		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern other document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: A copy of the International Preliminary Examination Report is enclosed for your convenience 		
<div style="border: 1px solid black; padding: 5px;"> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Invoice No. EH 608540192 US in an envelope addressed to:</p> <p style="text-align: center;">Commissioner of Patents and Trademarks Washington, D.C. 20231</p> <p>on this <u>4th</u> day of <u>October</u> 1996.</p> <p style="text-align: center;">  Pamela Scarbrough </p> <p style="text-align: right;"> <u>10/4/96</u> Date </p> </div>		

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.: PCT/IE 95/00025		ATTORNEY'S DOCKET NUMBER: 96.1252.US					
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$880.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$680.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445 (a)(2))... \$750.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$1010.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$ 94.00 <p style="text-align: center;">ENTER APPROPRIATE BASIC FEE AMOUNT</p>				CALCULATIONS		PTO USE ONLY			
				\$ 880.00					
				Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					
Claims		Number Filed		Number Extra		Rate			
Total Claims		20 -20=		0		X \$22.00			
Independent Claims		4 -3=		0		X \$78.00			
Multiple dependent claims(s) (if applicable)						+ \$250.00			
TOTAL OF ABOVE CALCULATIONS						\$			
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).						\$			
SUBTOTAL						= \$ 958.00			
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						= \$			
TOTAL NATIONAL FEE						= \$ 958.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 1.21(h)). \$40.00 per property						\$			
TOTAL FEES ENCLOSED						= \$ 958.00			
						Amount to be refunded:		\$	
						charged:			
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>958.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>05-0670</u> in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit and overpayment to Deposit Account No. <u>05-0670</u> . A duplicate copy of this sheet is enclosed.									
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <div style="display: flex; justify-content: space-between;"> <div style="width: 60%;"> Mary L. Severson, Ph.D. ELAN PHARMACEUTICAL RESEARCH CORPORATION 1300 Gould Drive Gainesville, GA 30504 770-534-8239 </div> <div style="width: 35%; text-align: right;">  SIGNATURE <u>Mary L. Severson</u> NAME <u>34,927</u> REGISTRATION NUMBER </div> </div>									